Cost-Effectiveness of Afatinib, Erlotinib, and Cisplatin/Pemetrexed for First-Line Treatment of Metastatic Egfr-Mutation Positive Non-Small Cell Lung Cancer
May 1, 2014, 00:00
10.1016/j.jval.2014.03.491
https://www.valueinhealthjournal.com/article/S1098-3015(14)00542-7/fulltext
Title :
Cost-Effectiveness of Afatinib, Erlotinib, and Cisplatin/Pemetrexed for First-Line Treatment of Metastatic Egfr-Mutation Positive Non-Small Cell Lung Cancer
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(14)00542-7&doi=10.1016/j.jval.2014.03.491
First page :
A84
Section Title :
Cancer
Open access? :
No
Section Order :
1537